血清肿瘤标志物CA19-9的临床应用研究

Study on clinical application of CA19-9

目的探讨血清肿瘤标志物糖类抗原19-9(CA19-9)在不同类型肿瘤患者及健康人血清中的检测水平,系统性地评价其在肿瘤中的临床应用价值。方法采用化学发光免疫蛋白定量分析法对767例肿瘤患者(病例组)及288例同期健康体检个体(对照组)进行血清CA19-9检测。结果在对照组中,CA19-9普遍具有较低的表达水平,均值为(14.2±8.9)IU/mL,但是在不同系统的恶性肿瘤中均发现血清CA19-9水平显著上升,在同一系统不同类型的恶性肿瘤当中,血清CA19-9水平也各有差异,呈现出表达水平的异质性。结论 CA19-9在食管癌、肝癌、胰腺癌、胆囊癌等恶性肿瘤中呈高水平表达,提示CA19-9在临床检测中具有较高的应用价值,但其在一些良性肿瘤和炎症病变中的高表达也提示临床在CA19-9的应用中仍需注意对相关良性肿瘤的鉴别分析。

Objective To evaluate the clinical application value of carbohydrate antigen 1 9-9 （CA1 9-9 ）in different kinds of tumors.Methods Serum levels of CA19-9 were detected in 767 tumor or benign tumor patients （case group）and 288 health sub-jects （control group）by using chemoluminescence assay.Results Serum level of CA19-9 in control group was （14.2＆#177;8.9）IU/mL,which was significantly lower than case group.Serum levels of CA19-9 were with differences in patients with cancers of differ-ent systems,and those in patients with different types of cancers of the same system were also with differences,indicating that ser-um CA19-9 expression levels could be heterogeneous in cancer patients.Conclusion High serum expression levels of CA19-9 could be detected in patients with esophageal carcinoma,liver cancer,pancreatic cancer,or gallbladder carcinoma and so on,indicating that CA1 9-9 might be with important clinical value.But high expression levels of serum CA1 9-9 in some benign tumors might indicate that more attention should be paid for the differential diagnosis of benign tumors in clinical application.